155 related articles for article (PubMed ID: 33287932)
1. Estimation levels of prostate-specific antigen, interleukin-8, oxidative stress and some inflammatory markers in sera of benign prostatic hyperplasia patients who have smoking habits as a risk factor.
Al-Barzinj RMGT
Cell Mol Biol (Noisy-le-grand); 2020 Oct; 66(7):124-130. PubMed ID: 33287932
[TBL] [Abstract][Full Text] [Related]
2. Malondialdehyde in benign prostate hypertrophy: a useful marker?
Merendino RA; Salvo F; Saija A; Di Pasquale G; Tomaino A; Minciullo PL; Fraccica G; Gangemi S
Mediators Inflamm; 2003 Apr; 12(2):127-8. PubMed ID: 12775364
[TBL] [Abstract][Full Text] [Related]
3. Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.
Wu T; Kasper S; Wong RM; Bracken B
Clin Genitourin Cancer; 2020 Apr; 18(2):e174-e179. PubMed ID: 31899150
[TBL] [Abstract][Full Text] [Related]
4. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
[TBL] [Abstract][Full Text] [Related]
5. Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases.
Menschikowski M; Hagelgans A; Fuessel S; Mareninova OA; Asatryan L; Wirth MP; Siegert G
Inflamm Res; 2013 Dec; 62(12):1063-72. PubMed ID: 24061501
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of serum protein-bound sialic acid in benign and malignant prostatic growth: possible role of oxidative stress in sialic acid homeostasis.
Goswami K; Nandeesha H; Koner BC; Nandakumar DN
Prostate Cancer Prostatic Dis; 2007; 10(4):356-9. PubMed ID: 17404581
[TBL] [Abstract][Full Text] [Related]
7. Hypoadiponectinemia, elevated iron and high-sensitivity C-reactive protein levels and their relation with prostate size in benign prostatic hyperplasia.
Nandeesha H; Eldhose A; Dorairajan LN; Anandhi B
Andrologia; 2017 Sep; 49(7):. PubMed ID: 27658341
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
9. Oxidised low-density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia.
Asare GA; Owusu-Boateng E; Asiedu B; Amoah BY; Essendoh E; Otoo RY
Andrologia; 2019 Sep; 51(8):e13321. PubMed ID: 31145504
[TBL] [Abstract][Full Text] [Related]
10. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
11. Profile of NF-κBp(65/NFκBp50) among prostate specific antigen sera levels in prostatic pathologies.
Bouraoui Y; Ben Jemaa A; Rodriguez G; Ben Rais N; Fraile B; Paniagua R; Sellemi S; Royuela M; Oueslati R
Pathol Biol (Paris); 2012 Oct; 60(5):301-5. PubMed ID: 21889270
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer.
Veltri RW; Miller MC; Zhao G; Ng A; Marley GM; Wright GL; Vessella RL; Ralph D
Urology; 1999 Jan; 53(1):139-47. PubMed ID: 9886603
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress in benign prostate hyperplasia.
Aryal M; Pandeya A; Gautam N; Baral N; Lamsal M; Majhi S; Chandra L; Pandit R; Das BK
Nepal Med Coll J; 2007 Dec; 9(4):222-4. PubMed ID: 18298008
[TBL] [Abstract][Full Text] [Related]
14. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum prolidase activity and oxidative stress markers in men with BPH and prostate cancer.
Kucukdurmaz F; Efe E; Çelik A; Dagli H; Kılınc M; Resim S
BMC Urol; 2017 Dec; 17(1):116. PubMed ID: 29233144
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and histomorphological changes in testosterone propionate-induced benign prostatic hyperplasia in male Wistar rats treated with ketogenic diet.
Kayode OT; Owolabi AV; Kayode AAA
Biomed Pharmacother; 2020 Dec; 132():110863. PubMed ID: 33113424
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
18. Combined ethanol extract of Funtumia africana and Abutilon mauritianium leaves improves the lipid profile and kidney function indices of benign prostatic hyperplasia in rats.
Uroko RI; Chukwu CN; Egba SI; Adamude FA; Ajuzie JC
Acta Sci Pol Technol Aliment; 2020; 19(4):395-404. PubMed ID: 33179480
[TBL] [Abstract][Full Text] [Related]
19. Impact of Prostate Specific Antigen and Testosterone Hormone Levels in Patients of Benign Prostatic Hyperplasia in Khartoum State-Sudan.
A M Alameen A; A M Osman T; A Elissidig S; Atif M
Pak J Biol Sci; 2020 Jan; 23(11):1431-1435. PubMed ID: 33274871
[TBL] [Abstract][Full Text] [Related]
20. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
